網膜静脈閉塞症の世界市場レポート 2024年

網膜静脈閉塞症の市場規模は近年急速に拡大しています。2023年の137億9,000万米ドルから2024年には154億3,000万米ドルへとCAGR11.9％で拡大します。実績期間の成長は、高齢化、画像診断の進歩、医薬品開発、糖尿病有病率の増加に起因しています。

眼疾患の有病率の増加が予想されることから、眼ドラッグデリバリー市場の今後の成長が期待されます。眼疾患は、眼球、視力、眼球周辺構造に影響を及ぼす幅広い疾患を包含します。腎静脈閉塞症の罹患率の増加が腎静脈閉塞症市場の成長に寄与しており、その結果、この症状に対処するための革新的な診断薬や治療薬に対する需要が高まっています。例えば、スイスに本部を置く国連機関である世界保健機関（WHO）は2023年3月、世界全体で約22億人が近視または遠視の視力障害を経験すると推定しています。白内障（9,400万人）と未矯正の屈折問題（8,840万人）が視覚障害や視力障害の主な原因です。さらに、緑内障（770万件）、角膜混濁（420万件）、糖尿病性網膜症（390万件）、トラコーマ（200万件）なども視力低下の原因となっています。したがって、眼疾患の有病率の増加が網膜静脈閉塞症市場の原動力となると思われます。

2023年の網膜静脈閉塞症市場で最大の地域は北米でした。アジア太平洋は予測期間中に最も急成長する地域となる見込みです。網膜静脈閉塞症レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の網膜静脈閉塞症市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 網膜動脈分枝閉塞症
• 網膜中心静脈閉塞症
• 世界の網膜静脈閉塞症市場、状態別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 非虚血性
• 虚血性
• 世界の網膜静脈閉塞症市場、診断別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 光干渉断層撮影法
• 眼底検査
• フルオレセイン血管造影
• 世界の網膜静脈閉塞症市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 抗血管内皮増殖因子
• コルチコステロイド薬
• レーザー網膜光凝固術
• 世界の網膜静脈閉塞症市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院と診療所
• 調査および学術センター
• その他のエンドユーザー

第7章 地域および国の分析

• 世界の網膜静脈閉塞症市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の網膜静脈閉塞症市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 網膜静脈閉塞症市場の競合情勢
• 網膜静脈閉塞症市場の企業プロファイル
  • Pfizer Inc.
  • Roche Holding AG
  • Merck &Co. Inc.
  • Bayer AG
  • Novartis AG

第31章 その他の主要および革新的な企業

• Bristol-Myers Squibb Company
• Amgen Inc.
• Allergan PLC
• Regeneron Pharmaceuticals Inc.
• Biogen Idec Inc.
• Vertex Pharmaceuticals Inc.
• Bausch Health Companies Inc.
• Carl Zeiss AG
• Santen Pharmaceutical Co. Ltd.
• Lumenis Ltd.
• Coherus Biosciences Inc.
• Genentech Inc.
• Topcon Corporation
• Nidek Co. Ltd
• IRIDEX Corporation

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

“Retinal Vein Occlusion Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on retinal vein occlusion market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for retinal vein occlusion? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The retinal vein occlusion market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Type: Branch Retinal Artery Occlusion; Central Retinal Vein Occlusion
• 2) By Condition: Non-Ischemic; Ischemic
• 3) By Diagnosis: Optical Coherence Tomography; Fundoscopic Examination; Fluorescein Angiography
• 4) By Treatment: Antivascular Endothelial Growth Factor; Corticosteroid Drugs; Laser Retinal Photocoagulation
• 5) By End User: Hospitals And Clinics; Research And Academics Centers; Other End-Users
• Companies Mentioned: Pfizer Inc.; Roche Holding AG; Merck & Co. Inc.; Bayer AG; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Retinal vein occlusion (RVO) is a medical condition occurring when a blockage or hindrance in the veins that carry blood away from the retina, the light-sensitive tissue at the rear of the eye. The prevention of RVO involves managing other illnesses related to blood vessels that increase the risk of RVO development. This management includes adopting a low-fat diet, engaging in regular exercise, and maintaining a healthy body weight.

The main categories of retinal vein occlusion encompass branch retinal artery occlusion and central retinal vein occlusion. Branch retinal artery occlusion is characterized by reduced arterial blood flow to a branch of the central retinal artery, resulting in ischemic damage in the affected area of the retina. Treatment for this condition typically involves ocular hypotensive drugs like topical timolol or intravenous (IV) and oral acetazolamide. These conditions are further divided into non-ischemic and ischemic types, with diagnosis relying on methods such as optical coherence tomography, fundoscopic examination, and fluorescein angiography. Treatment strategies encompass antivascular endothelial growth factor therapy, corticosteroid medications, and laser retinal photocoagulation, with end users including hospitals, clinics, research and academic centers, among others.

The retinal vein occlusion market research report is one of a series of new reports from The Business Research Company that provides retinal vein occlusion market statistics, including retinal vein occlusion industry global market size, regional shares, competitors with a retinal vein occlusion market share, detailed retinal vein occlusion market segments, market trends and opportunities and any further data you may need to thrive in the retinal vein occlusion industry. This retinal vein occlusion market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The retinal vein occlusion market size has grown rapidly in recent years. It will grow from $13.79 billion in 2023 to $15.43 billion in 2024 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to aging population, advancements in diagnostic imaging, pharmaceutical developments, increased diabetes prevalence.

The retinal vein occlusion market size is expected to see rapid growth in the next few years. It will grow to $23.08 billion in 2028 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to innovative treatment approaches, telemedicine and remote monitoring, personalized medicine, regulatory approvals. Major trends in the forecast period include non-invasive treatment options, gene therapy breakthroughs, patient-centric care, digital health tools.

The anticipated rise in the prevalence of eye disorders is poised to stimulate the growth of the ocular drug delivery market in the future. Eye disorders encompass a broad spectrum of conditions affecting the eyes, vision, or the structures surrounding the eyes. The increasing incidence of renal vein occlusion is contributing to the growth of the renal vein occlusion market, resulting in a heightened demand for innovative diagnostics and treatments to address this condition. For example, in March 2023, the World Health Organization, a United Nations agency based in Switzerland, estimated that globally, around 2.2 billion people will experience impairment in near- or far-sighted vision. Cataracts (94 million) and uncorrected refractive issues (88.4 million) represent the primary causes of visual impairment or impaired vision. Additionally, other common contributors to vision loss include glaucoma (7.7 million cases), corneal opacities (4.2 million cases), diabetic retinopathy (3.9 million cases), and trachoma (2 million cases). Hence, the increasing prevalence of eye disorders will be a driving force behind the retinal vein occlusion market.

The expected increase in the incidence of glaucoma is set to propel the growth of the retinal vein occlusion market in the coming years. Glaucoma is an eye condition characterized by elevated intraocular pressure within the eye, posing a risk to the optic nerve and potentially leading to vision loss or blindness if left untreated. The prevalence of glaucoma cases significantly contributes to the expansion of retinal vein occlusion, underscoring the crucial need for effective prevention and management strategies. These strategies aim to reduce the risk of retinal vein occlusion and enhance overall quality of life. For instance, as of October 2022, the BrightFocus Foundation, a U.S.-based nonprofit organization dedicated to advancing research and support for macular degeneration and glaucoma, reported a current global estimate of 80 million individuals with glaucoma, with a projected increase to over 111 million by the year 2040. Therefore, the rising incidence of glaucoma will drive the growth of the optic atrophy management market.

A potential obstacle to the expansion of the retinal vein occlusion (RVO) market during the forecast period is the decreased sales of medicines. This decline in medicine sales has the potential to impact the market by reducing the revenue generated by pharmaceutical companies and limiting the availability of treatment options. For instance, in May 2023, the Assistant Secretary for Planning and Evaluation (ASPE), the principal advisor to the Secretary of the U.S. Department of Health and Human Services on policy development, reported that following a shortage, there was a notable decrease in medicine sales volume, ranging between 28% and 35% compared to the year before the drug entered a shortage. Consequently, the diminished sales of medicines are affecting the growth of the retinal vein occlusion market.

Companies operating within the retinal vein occlusion market are embracing innovative approaches to enhance patient care and treatment outcomes while maintaining their competitive position in the market. Progress in drug development holds the potential to expand the range of treatment options for RVO, delivering more precise and effective treatments. For instance, in April 2023, Iridex Corporation, a U.S.-based ophthalmic medical technology company, introduced the next-generation Iridex PASCAL. This cutting-edge platform integrates rapid and precise pattern scanning capabilities, endpoint management technology, pattern scanning laser trabeculoplasty, and micropulse technology into a more compact, ergonomically designed integrated laser platform. This advancement is designed to offer personalized care to patients with retinal diseases.

In September 2021, Boston Scientific Corporation, a U.S.-based medical device manufacturer, completed the acquisition of the surgical business of Lumenis Ltd. for $1.07 billion. This strategic move by Boston Scientific aims to integrate the Lumenis laser portfolio and establish a global surgical laser center of excellence in Yokneam, focusing on driving innovation to assist surgeons in enhancing patient care. Lumenis Ltd. is an Israel-based manufacturer of surgical and laser equipment designed for ophthalmic and aesthetic applications.

Major players in the retinal vein occlusion market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Amgen Inc., Allergan PLC, Regeneron Pharmaceuticals Inc., Biogen Idec Inc., Vertex Pharmaceuticals Inc., Bausch Health Companies Inc., Carl Zeiss AG, Santen Pharmaceutical Co. Ltd., Lumenis Ltd., Coherus Biosciences Inc., Genentech Inc., Topcon Corporation, Nidek Co. Ltd., IRIDEX Corporation, Alimera Sciences Inc., Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Kodiak Sciences Inc., Ellex Medical Lasers Ltd., Adverum Biotechnologies Inc., Avik Pharmaceutical Limited (Avik), Outlook Therapeutics Inc., Annexin Pharmaceuticals AB, Ingenia Therapeutics Inc .

North America was the largest region in the retinal vein occlusion market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in retinal vein occlusion report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the retinal vein occlusion market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The retinal vein occlusion market consists of revenues earned by entities by providing services such as surgery and pan retinal photocoagulation. The market value includes the value of related goods sold by the service provider or included within the service offering. The retinal vein occlusion market also includes sales of ranibizumab and aflibercept. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Retinal Vein Occlusion Market Characteristics

3. Retinal Vein Occlusion Market Trends And Strategies

4. Retinal Vein Occlusion Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Retinal Vein Occlusion Market Size and Growth

• 5.1. Global Retinal Vein Occlusion Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Retinal Vein Occlusion Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Retinal Vein Occlusion Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Retinal Vein Occlusion Market Segmentation

• 6.1. Global Retinal Vein Occlusion Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Branch Retinal Artery Occlusion
• Central Retinal Vein Occlusion
• 6.2. Global Retinal Vein Occlusion Market, Segmentation By Condition, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Non-Ischemic
• Ischemic
• 6.3. Global Retinal Vein Occlusion Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Optical Coherence Tomography
• Fundoscopic Examination
• Fluorescein Angiography
• 6.4. Global Retinal Vein Occlusion Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Antivascular Endothelial Growth Factor
• Corticosteroid Drugs
• Laser Retinal Photocoagulation
• 6.5. Global Retinal Vein Occlusion Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals And Clinics
• Research And Academics Centers
• Other End-Users

7. Retinal Vein Occlusion Market Regional And Country Analysis

• 7.1. Global Retinal Vein Occlusion Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Retinal Vein Occlusion Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Retinal Vein Occlusion Market

• 8.1. Asia-Pacific Retinal Vein Occlusion Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Retinal Vein Occlusion Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Retinal Vein Occlusion Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Retinal Vein Occlusion Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Retinal Vein Occlusion Market

• 9.1. China Retinal Vein Occlusion Market Overview
• 9.2. China Retinal Vein Occlusion Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Retinal Vein Occlusion Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Retinal Vein Occlusion Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Retinal Vein Occlusion Market

• 10.1. India Retinal Vein Occlusion Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Retinal Vein Occlusion Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Retinal Vein Occlusion Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Retinal Vein Occlusion Market

• 11.1. Japan Retinal Vein Occlusion Market Overview
• 11.2. Japan Retinal Vein Occlusion Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Retinal Vein Occlusion Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Retinal Vein Occlusion Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Retinal Vein Occlusion Market

• 12.1. Australia Retinal Vein Occlusion Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Retinal Vein Occlusion Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Retinal Vein Occlusion Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Retinal Vein Occlusion Market

• 13.1. Indonesia Retinal Vein Occlusion Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Retinal Vein Occlusion Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Retinal Vein Occlusion Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Retinal Vein Occlusion Market

• 14.1. South Korea Retinal Vein Occlusion Market Overview
• 14.2. South Korea Retinal Vein Occlusion Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Retinal Vein Occlusion Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Retinal Vein Occlusion Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Retinal Vein Occlusion Market

• 15.1. Western Europe Retinal Vein Occlusion Market Overview
• 15.2. Western Europe Retinal Vein Occlusion Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Retinal Vein Occlusion Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Retinal Vein Occlusion Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Retinal Vein Occlusion Market

• 16.1. UK Retinal Vein Occlusion Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Retinal Vein Occlusion Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Retinal Vein Occlusion Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Retinal Vein Occlusion Market

• 17.1. Germany Retinal Vein Occlusion Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Retinal Vein Occlusion Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Retinal Vein Occlusion Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Retinal Vein Occlusion Market

• 18.1. France Retinal Vein Occlusion Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Retinal Vein Occlusion Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Retinal Vein Occlusion Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Retinal Vein Occlusion Market

• 19.1. Italy Retinal Vein Occlusion Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Retinal Vein Occlusion Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Retinal Vein Occlusion Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Retinal Vein Occlusion Market

• 20.1. Spain Retinal Vein Occlusion Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Retinal Vein Occlusion Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Retinal Vein Occlusion Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Retinal Vein Occlusion Market

• 21.1. Eastern Europe Retinal Vein Occlusion Market Overview
• 21.2. Eastern Europe Retinal Vein Occlusion Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Retinal Vein Occlusion Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Retinal Vein Occlusion Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Retinal Vein Occlusion Market

• 22.1. Russia Retinal Vein Occlusion Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Retinal Vein Occlusion Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Retinal Vein Occlusion Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Retinal Vein Occlusion Market

• 23.1. North America Retinal Vein Occlusion Market Overview
• 23.2. North America Retinal Vein Occlusion Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Retinal Vein Occlusion Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Retinal Vein Occlusion Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Retinal Vein Occlusion Market

• 24.1. USA Retinal Vein Occlusion Market Overview
• 24.2. USA Retinal Vein Occlusion Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Retinal Vein Occlusion Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Retinal Vein Occlusion Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Retinal Vein Occlusion Market

• 25.1. Canada Retinal Vein Occlusion Market Overview
• 25.2. Canada Retinal Vein Occlusion Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Retinal Vein Occlusion Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Retinal Vein Occlusion Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Retinal Vein Occlusion Market

• 26.1. South America Retinal Vein Occlusion Market Overview
• 26.2. South America Retinal Vein Occlusion Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Retinal Vein Occlusion Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Retinal Vein Occlusion Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Retinal Vein Occlusion Market

• 27.1. Brazil Retinal Vein Occlusion Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Retinal Vein Occlusion Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Retinal Vein Occlusion Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Retinal Vein Occlusion Market

• 28.1. Middle East Retinal Vein Occlusion Market Overview
• 28.2. Middle East Retinal Vein Occlusion Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Retinal Vein Occlusion Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Retinal Vein Occlusion Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Retinal Vein Occlusion Market

• 29.1. Africa Retinal Vein Occlusion Market Overview
• 29.2. Africa Retinal Vein Occlusion Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Retinal Vein Occlusion Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Retinal Vein Occlusion Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Retinal Vein Occlusion Market Competitive Landscape And Company Profiles

• 30.1. Retinal Vein Occlusion Market Competitive Landscape
• 30.2. Retinal Vein Occlusion Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Roche Holding AG
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Merck & Co. Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Bayer AG
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Novartis AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Retinal Vein Occlusion Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. Amgen Inc.
• 31.3. Allergan PLC
• 31.4. Regeneron Pharmaceuticals Inc.
• 31.5. Biogen Idec Inc.
• 31.6. Vertex Pharmaceuticals Inc.
• 31.7. Bausch Health Companies Inc.
• 31.8. Carl Zeiss AG
• 31.9. Santen Pharmaceutical Co. Ltd.
• 31.10. Lumenis Ltd.
• 31.11. Coherus Biosciences Inc.
• 31.12. Genentech Inc.
• 31.13. Topcon Corporation
• 31.14. Nidek Co. Ltd
• 31.15. IRIDEX Corporation

32. Global Retinal Vein Occlusion Market Competitive Benchmarking

33. Global Retinal Vein Occlusion Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Retinal Vein Occlusion Market

35. Retinal Vein Occlusion Market Future Outlook and Potential Analysis

• 35.1 Retinal Vein Occlusion Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Retinal Vein Occlusion Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Retinal Vein Occlusion Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer